


PHARMACEUTICAL 2019

DURECT CORP Rank 210 of 371







PHARMACEUTICAL 2019

DURECT CORP Rank 210 of 371



The relative strengths and weaknesses of DURECT CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DURECT CORP compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 129% points. The greatest weakness of DURECT CORP is the variable Research and Development, reducing the Economic Capital Ratio by 100% points.

The company's Economic Capital Ratio, given in the ranking table, is -195%, being 136% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	41,740
Cost of Goods Sold	4,263
Intangible Assets	6,399
Liabilities, Current	7,662
Liabilities, Non-Current	0
Other Assets	1,255
Other Compr. Net Income	1.0
Other Expenses	0
Other Liabilities	0
Other Net Income	-1,703
Property and Equipment	605
Research and Development	25,501
Revenues	18,564
Selling, General and Administrative Expense	12,419

Output Variable	Value in 1000 USD
Assets	49,999
Liabilities	7,662
Expenses	42,183
Stockholders Equity	42,337
Net Income	-25,322
Comprehensive Net Income	-25,322
Economic Capital Ratio	-195%